CLOs on the Move

La Jolla Bioengineering Institute

www.ljbi.org

 
La Jolla Bioengineering Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 50K-100K
  • Annual Revenue: $1-10 Million
  • www.ljbi.org
  • 3535 General Atomics Ct Ste 210
    San Diego, CA USA 92121
  • Phone: 858.456.7500

Executives

Name Title Contact Details

Similar Companies

4G Clinical

4G Clinicals suite of innovative RTSM and clinical supply optimization software provides the right-sized support for any phase or trial complexity. At 4G Clinical, all studies are supported by a team of RTSM experts to advise trial teams on the best path forward. Our operations team distinguishes itself through their extensive industry expertise and deep understanding of trial designs and mid-study adjustments. 4G Clinical is committed to helping sponsors and CROs follow the science, wherever it may lead, as quickly and as safely as we can. While we will not discover the next novel compound in the lab, we are doing our part by leveraging our extensive experience and technological innovations to bring speed and agility to clinical trials. As a critical partner throughout clinical development, we can help you seamlessly transition and scale your trials through both protocol and supply complexities to help bring crucial medicines to those who need them, faster. To learn more about how we are tackling the bottlenecks in clinical trials through our innovative solutions, Prancer RTSM® and 4C Supply®, visit us at www.4gclinical.com.

Ankyra Therapeutics

Ankyra is developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response.

Enthalpy Analytical

Enthalpy Analytical, Inc. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Panacos Pharmaceuticals

Panacos Pharmaceuticals, Inc. is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea`s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families.